A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor

被引:166
作者
Bledsoe, RK
Madauss, KP
Holt, JA
Apolito, CJ
Lambert, MH
Pearce, KH
Stanley, TB
Stewart, EL
Trump, RP
Willson, TM
Williams, SP
机构
[1] GlaxoSmithKline Inc, Dept Gene Express & Prot Biochem, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline Inc, Dept Computat Analyt & Struct Sci, Res Triangle Pk, NC 27709 USA
[3] GlaxoSmithKline Inc, Dept High Throughput Biol, Res Triangle Pk, NC 27709 USA
[4] GlaxoSmithKline Inc, Dept High Throughput Chem, Discovery Res, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1074/jbc.M504098200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ligand binding is the first step in hormone regulation of mineralocorticoid receptor (MR) activity. Here, wereport multiple crystal structures of MR (NR3C2) bound to both agonist and antagonists. These structures combined with mutagenesis studies reveal that maximal receptor activation involves an intricate ligand-mediated hydrogen bond network with Asn(770) which serves dual roles: stabilization of the loop preceding the C-terminal activation function-2 helix and direct contact with the hormone ligand. In addition, most activating ligands hydrogen bond to Thr(945) on helix 10. Structural characterization of the naturally occurring S810L mutant explains how stabilization of a helix 3/helix 5 interaction can circumvent the requirement for this hydrogen bond network. Taken together, these results explain the potency of MR activation by aldosterone, the weak activation induced by progesterone and the antihypertensive agent spironolactone, and the binding selectivity of cortisol over cortisone.
引用
收藏
页码:31283 / 31293
页数:11
相关论文
共 48 条
[1]   General overview of mineralocorticoid hormone action [J].
Agarwal, MK ;
Mirshahi, M .
PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :273-326
[2]  
ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072
[3]   CLONING OF HUMAN MINERALOCORTICOID RECEPTOR COMPLEMENTARY-DNA - STRUCTURAL AND FUNCTIONAL KINSHIP WITH THE GLUCOCORTICOID RECEPTOR [J].
ARRIZA, JL ;
WEINBERGER, C ;
CERELLI, G ;
GLASER, TM ;
HANDELIN, BL ;
HOUSMAN, DE ;
EVANS, RM .
SCIENCE, 1987, 237 (4812) :268-275
[4]  
Auwerx J, 1999, CELL, V97, P161
[5]   A single amino acid mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11β-substituted spirolactones [J].
Auzou, G ;
Fagart, J ;
Souque, A ;
Hellal-Lévy, C ;
Wurtz, JM ;
Moras, D ;
Rafestin-Oblin, ME .
MOLECULAR PHARMACOLOGY, 2000, 58 (04) :684-691
[6]   Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition [J].
Bledsoe, RK ;
Montana, VG ;
Stanley, TB ;
Delves, CJ ;
Apolito, CJ ;
McKee, DD ;
Consler, TG ;
Parks, DJ ;
Stewart, EL ;
Willson, TM ;
Lambert, MH ;
Moore, JT ;
Pearce, KH ;
Xu, HE .
CELL, 2002, 110 (01) :93-105
[7]  
BRILLA CG, 1992, J LAB CLIN MED, V120, P893
[8]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[9]   Expression of the progesterone receptor and progesterone-metabolising enzymes in the female and male human kidney [J].
Bumke-Vogt, C ;
Bähr, V ;
Diederich, S ;
Herrmann, SM ;
Anagnostopoulos, I ;
Oelkers, W ;
Quinkler, M .
JOURNAL OF ENDOCRINOLOGY, 2002, 175 (02) :349-364
[10]   MECHANISM OF THE ANTI-MINERALOCORTICOID EFFECTS OF SPIROLACTONES [J].
CORVOL, P ;
CLAIRE, M ;
OBLIN, ME ;
GEERING, K ;
ROSSIER, B .
KIDNEY INTERNATIONAL, 1981, 20 (01) :1-6